Follow-on Biologics (Bio-Similars)
Follow-on biologics, or biosimilars, will play an increasingly important role in therapeutic development, and more companies are reprioritizing their development activities to include biosimilars.
PreEMT provides the solution to a significant challenge that will accompany the production of biosimilars, the requirement for substantially decreased manufacturing costs, required to enable the biosimilar to compete with the original reference biologic as well as other follow-on biologic competitors. High pressure treatment through PreEMT is an innovative manufacturing approach that has the potential to decrease manufacturing costs by recovering and folding protein aggregates.
Further, BaroFold’s patented protein manufacturing technology offers companies novel intellectual property for ensuring freedom-to-operate in areas where the branded manufacturer has established blocking intellectual property.